BioCentury | Feb 21, 2019
Company News

HaiHe forms joint venture with CSPC, narrows focus to oncology

Shanghai HaiHe Biopharma Co. Ltd. (Shanghai, China) formed a joint venture with CSPC Pharmaceutical Group Ltd. (HKSE:1093) to develop and commercialize five of HaiHe’s programs, mostly outside of oncology. Financial terms were not disclosed. HaiHe...
BioCentury | Feb 19, 2019
Company News

HaiHe forms joint venture with CSPC, narrows focus to oncology

Shanghai HaiHe Biopharma Co. Ltd. (Shanghai, China) formed a joint venture with CSPC Pharmaceutical Group Ltd. (HKSE:1093) to develop and commercialize five of HaiHe’s programs, mostly outside of oncology. Financial terms were not disclosed. HaiHe...
BioCentury | Feb 11, 2019
Distillery Therapeutics

Neurology

INDICATION: Pain In vitro and rat studies identified a benzimidazole-based PTGER4 antagonist that could help treat pain. High throughput screening of Bayer AG's compound library, in vitro enzymatic activity assays and optimization of hits yielded...
BioCentury | Nov 15, 2018
Product R&D

Tempest takes PPAR alpha into cancer

Tempest Therapeutics Inc.’s first data from its preclinical PPARα program gave it the support it was looking for to repurpose the cardiovascular target for cancer. Tapping into the emerging field of cancer immuno-metabolism, Tempest is...
BioCentury | Aug 29, 2018
Distillery Therapeutics

Infectious disease

INDICATION: Bacterial infection Mouse studies suggest antagonizing PTGER4 could help treat infectious colitis. In a mouse model of Citrobacter rodentium -induced colitis, a PTGER4 antagonist tool compound decreased weight loss, numbers of infectious bacteria in...
BioCentury | Jun 29, 2018
Financial News

Adlai Nortye raises $50M series B

Chinese immunotherapy company Adlai Nortye Biopharma Co. Ltd. (Hangzhou, China) raised over $50 million in a series B round led by YuanMing Capital. Matrix Partners China, DT Capital Partners and Yahui Precision Medicine Fund also...
BioCentury | Jun 26, 2018
Financial News

Adlai Nortye raises $50M in series B

Chinese immunotherapy company Adlai Nortye Biopharma Co. Ltd. (Hangzhou, China) raised over $50 million in a series B round led by YuanMing Capital. Matrix Partners China, DT Capital Partners and Yahui Precision Medicine Fund also...
BioCentury | Apr 26, 2018
Targets & Mechanisms

Raising metabolism

In the wake of the failure of ECHO-301, drug developers are asking whether the trial design or the target is at fault. But while the value of IDO1 as a target is still in doubt,...
BioCentury | Jan 26, 2018
Company News

Adlai Nortye receives rights to solid tumor candidate E7046 from Eisai

Eisai Co. Ltd. (Tokyo:4523) granted Adlai Nortye Co. Ltd. (NEEQ:870946) exclusive, worldwide rights outside of parts of Asia to develop and commercialize solid tumor candidate E7046. Specifically, the deal excludes Japan, Korea, Taiwan, Thailand, India,...
BioCentury | Dec 15, 2017
Company News

BMS, Ono partner for prostaglandin receptor antagonist

Ono Pharmaceutical Co. Ltd. (Tokyo:4528) granted Bristol-Myers Squibb Co. (NYSE:BMY) exclusive rights to develop and commercialize ONO-4578 worldwide except in Japan, South Korea, Taiwan, China and Association of Southeast Asian Nations (ASEAN) countries. Ono will...
Items per page:
1 - 10 of 53